Year: 2026
Type: article
Abstract: Dear Colleagues, Among all genitourinary malignancies, muscle-invasive bladder cancer (MIBC) is arguably the "winner" in 2025 when it comes to therapeutic progress.Two landmark phase III trials, KEYNOTE-905/EV-303 and IMvigor011, were presented at the European Society for Medical Oncology (ESMO) 2025 Congress and highlighted at the Swiss Oncology and Hematology Congress (SOHC).In particular, for the patient population addressed in KEYNOTE-905 -cisplatin-ineligible -this trial has delivered long-awaited advances to those historically underserved.
Author: Vogl
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7118188771
FWCI:
Cites:
Cited by:
Related to: